Disclosure of interest  This work did not receive funding from external sources. Over the past few years, Dr. Fineberg has received financial support in various forms from the following: Shire, Otsuka, Lundbeck, Glaxo-SmithKline, Servier, Cephalon, Astra Zeneca, Jazz Pharmaceuticals, Bristol Myers Squibb, Novartis, Medical Research Council (UK), National Institute for Health Research (UK), Wellcome Foundation, European College of Neuropsychopharmacology, UK College of Mental Health Pharmacists, British Association for Psychopharmacology, International College of Obsessive-Compulsive Spectrum Disorders, International Society for Behavioural Addiction, World Health Organization, Royal College of Psychiatrists. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1959

EW0091
Psychiatric co-morbidities in a French cohort of adults with high-functioning autism (HFA)  
A. Gaman1,2,3,∗, O. Godin2, I. Scheid1,2, D. Monnet1,3, E. Murzi1,∗, A. Martinez Teruel1,∗, F. Amsellem2,5,6, H. Laouamri4, K. Souyris4, J. Houneou2,∗, T. Infor5, R. Delorme2,5,6, M. Leboyer1,2,∗  
1 Hospital Albert Chenevier AP–HP, Psychiatry, Créteil, France  
2 Inserm, U955 Translational Psychiatry, Paris, France  
3 Fondation Fondamental, Centre Expert Asperger, Paris, France  
4 Fondation Fondamental, Informatics and Data Base, Paris, France  
5 Institute Pasteur, Human Genetics and Cognitive Studies, Paris, France  
6 Hôpital “Robert Debré”, Child and Adolescent Psychiatry, Paris, France  
7 Neurospin, Uniact Psychiatry Team, Paris, France  
8 Roche, Cooperative Group, Basel, France  
∗ Corresponding author.

Background and rationale  Psychiatric co-morbidities are shown to be very prevalent in patients diagnosed with Autism Spectrum Disorder (ASD), up high to 53% for mood, 50% anxiety and 43% for ADHD disorders in an European cohort of adults with HFA. Using a new approach, our study proposes to explore aspects of co-morbidities in the largest French cohort of HFA adults (C0733/InfoR) by implying qualitative and quantitative clinical tools.

Aims  To explore: (1) the prevalence rates of psychiatric co-morbidities; (2) the interplay between co-morbidities and the ASD symptoms.

Methods  Diagnosis was made according to DSM 5 criteria. Dimensional evaluation used Social Responsiveness Scale (SRS), Systemizing Quotient (SQ) and Empathy Quotient (EQ). We used T-test, Mann–Whitney test and linear regression models.

Results  We included 103 patients (mean age 29.3, sex ratio M/F: 3.4:1). Lifetime prevalence rates of 53.5% for depressive disorder 73.5% for anxiety disorders and 37.5% for ADHD were found. Subjects with psychotic co-morbid symptoms had a more severe social deficit (SRS score 66.2 vs 77.9 P<0.05); patients with ADHD, lower cognition (mean IQ total 107.7 vs 99.0 P<0.05). SQs (P<0.05) were significantly higher in patients with co-morbid psychosis, dysthymia, suicide attempts, and depressive disorders and directly correlated with age (β=0.35, P<0.05). SQ and EQ were inversely correlated.

Discussion  The results reproduce the high prevalence of co-morbidities in other studies and explore its association with social functioning and cognition. Identification of associated psychiatric conditions in subjects with HFA is therefore a crucial clinical issue potentially guiding the treatment.

Disclosure of interest  The authors have not supplied their declaration of competing interest.

EW0092
Group experience and dual pathology and additions in a regional hospital in Spain  
M.G. García Jiménez  
Psychiatrist, Madrid, Spain

Introduction  Dual pathology is a term applied to those subjects suffering simultaneously from addiction and other mental disorder. Group psychotherapy can be used in people who have both diagnoses with good results in improvement of addiction and disease stabilization.

Objectives  The purpose of this study is to analyse to efficacy of a group of psychotherapy for patients with alcohol addiction and other mental disorder, and analyse the presence of personality disorder in this group and how it affects its evolution.

Methods  The study was conducted on a sample of 16 patients diagnosed with alcohol abuse or dependence with psychiatric co-morbidity who attended a therapy group for 6 months from January16 to June16. The study was conducted in ambulatory care (outpatient), being an open and heterogeneous group.

Results  Main diagnosis was unspecified personality disorder and mood disorder (25%) followed by borderline personality disorder and mood disorder (18.75%), attention deficit disorder and hyperactivity (18.75%), mood disorder (12.5%), substance use disorder without other psychiatric co-morbidity (12.5%), narcissistic personality disorder (6.25%) and impulse control disorder (6.25%). Regarding progress in the stages of change, results were as follows: 31.5% of patients progressed to the stage of preparation for action, 25% alternating periods of abstinence from alcohol with brief relapse, 25% advanced to the stage of action, 18.5% managed to stay alcohol withdrawn.

Conclusions  In our sample, we can conclude that a therapeutic group including patients at different stages of change and diagnoses is positive. At the end, improvement in mood and anxiety was observed.

Disclosure of interest  The author has not supplied his/her declaration of competing interest.

EW0093
The impact of cannabis in Schizophrenia: Paup three-year longitudinal study on outcome and functioning after a first episode of psychosis  
M. Gomez Revuelta1,∗, M. Juncal Ruiz2, O. Porta Olivares2, M. Fernández Rodríguez2,∗, D. Abejas Diez2, L. Sánchez Blanco2, R. Landera Rodríguez2, R. Medina Blanco2, B. Crespo Facorro2, I. Madrazo Del Río Horta2, R. Gutierrez Martin2  
1 Hospital Universitario de Álava-Sede Santiago. Vitoria-Gasteiz, Psychiatry, Vitoria-Gasteiz, Spain  
2 Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain  
∗ Corresponding author.

Introduction  The association between cannabis and psychosis makes crucial the intervention on cannabis use disorder at first episodes of psychosis (FEP), especially among young population. In this group of patients, the harmful potential of cannabis is more evident by its influence on neurodevelopment. However, the nature of the association cannabis–psychosis is not clearly described. It seems to represent a mediating factor for an increased risk of psychosis in healthy and high-risk populations, determining an earlier age of onset and worsening long term outcome.

Objectives  To assess the impact of cannabis in terms of functional and clinical prognosis in patients recruited after a FEP.